# CORRESP — Kairos Pharma, LTD.  (KAPA)  (CIK 0001962011)

> <strong>Kairos Pharma, LTD.  (KAPA)  (CIK 0001962011) → SEC staff</strong> · filed 2026-01-21 · ticker KAPA · SIC 2834

## What is this

A CORRESP letter is the company's written reply to the SEC during a filing review. Responses include accounting position arguments, restatement assessments, and clarifying disclosures. Released to EDGAR alongside the SEC's UPLOAD letters.

## Key facts

- **Accession number:** 0001493152-26-002996
- **Form:** CORRESP
- **Filer:** Kairos Pharma, LTD.  (KAPA)  (CIK 0001962011)
- **CIK:** 0001962011
- **Ticker:** KAPA
- **Filed:** 2026-01-21
- **SIC industry:** 2834
- **HQ:** Los Angeles, CA

## Primary source

PDF letter: https://www.sec.gov/Archives/edgar/data/1962011/000149315226002996/filename1.htm

EDGAR review history for this filer: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1962011&type=UPLOAD&dateb=&owner=include&count=40

## Other comment-letter activity for Kairos Pharma, LTD.  (KAPA)  (CIK 0001962011)

- UPLOAD — 2026-01-15 — /comment-letter/0000000000-26-000555

## Citation

> US Securities and Exchange Commission, EDGAR CORRESP comment letter, Kairos Pharma, LTD.  (KAPA)  (CIK 0001962011) (CIK 0001962011), filed 2026-01-21, accession 0001493152-26-002996. Retrieved via MORVS 2026-11-12 from https://api.morvs.ai/comment-letter/0001493152-26-002996.

---

*[SEC comment letters dataset](/datasets/sec-comment-letters) · CC0 1.0*